Virtus LifeSci Biotech Clinical Trials ETF
14 hedge funds and large institutions have $3.78M invested in Virtus LifeSci Biotech Clinical Trials ETF in 2016 Q2 according to their latest regulatory filings, with 4 funds opening new positions, 2 increasing their positions, 4 reducing their positions, and 2 closing their positions.
New
Increased
Maintained
Reduced
Closed
more first-time investments, than exits
New positions opened: | Existing positions closed:
more funds holding
Funds holding: →
more capital invested
Capital invested by funds: $ → $
less repeat investments, than reductions
Existing positions increased: | Existing positions reduced:
Holders
14
Holding in Top 10
–
Calls
–
Puts
–
Top Buyers
| 1 | +$291K | |
| 2 | +$280K | |
| 3 | +$155K | |
| 4 |
SG Americas Securities
New York
|
+$151K |
| 5 |
MFS
MSI Financial Services
Springfield,
Massachusetts
|
+$18.2K |
Top Sellers
| 1 | -$441K | |
| 2 | -$213K | |
| 3 | -$115K | |
| 4 |
UBS Group
Zurich,
Switzerland
|
-$9K |
| 5 |
LTFS
Ladenburg Thalmann Financial Services
Miami,
Florida
|
-$3.58K |